Oncolytic adenovirus encoding a B7 protein
View Patent ↗The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
1. A replication competent oncolytic adenovirus comprising SEQ ID NO: 20.
2. A pharmaceutical formulation of an adenovirus according to claim 1 , and a diluent or carrier.
3. A pharmaceutical formulation according to claim 2 , wherein the formulation is for parenteral administration.
4. A pharmaceutical formulation according to claim 3 , wherein the formulation comprises 2×10 12 viral particles/mL.
5. A pharmaceutical formulation according to claim 4 , wherein the virus particles are formulated in 5 mM HEPES, 20% glycerol with a final pH of 7.8.
6. A method of treating colorectal cancer comprising administering a therapeutically effective amount of a replication competent oncolytic adenovirus comprising SEQ ID NO: 20.
7. A method of treating colorectal cancer comprising administering a therapeutically effective amount of a pharmaceutical formulation comprising a replication competent oncolytic adenovirus comprising SEQ ID NO: 20 and a diluent or carrier.
8. A method of treatment according to claim 7 , wherein the pharmaceutical formulation is administered parentally.
9. A method according to claim 8 , wherein the dose per administration is in the range of 1×10 10 and 1×10 14 virus particles.